Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

20
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
20
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

232
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
232
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

46
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
46
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Complete Revascularization in Acute Myocardial Infarction Patients With High Bleeding Risk and Multivessel Disease.

Journal of the American Heart Association·2026
Same author

Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.

Journal of lipid and atherosclerosis·2026
Same author

Feasibility of Distal Radial Access in the Use of a Large-Bore Sheath for Percutaneous Coronary Intervention: Real-World Evidence From the Nationwide Cohort.

Korean circulation journal·2026
Same author

Early Initiation of Sodium-Glucose Cotransporter-2 Inhibitors in Acute Heart Failure: Reassurance Beyond Statistical Significance.

Korean circulation journal·2026
Same author

A Survey of Healthcare Professionals' Awareness of Vaccination in Patients With Heart Failure.

International journal of heart failure·2026
Same author

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Journal of the American Heart Association·2026

Related Experiment Video

Updated: Aug 18, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K

BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.

Chang-Hwan Yoon1, Ju-Seung Kwun1, Young Jin Choi2

  • 1Cardiovascular Center, Department of Internal Medicine, Seoul National University Bundang Hospital, Republic of Korea (C.-H.Y., J.-S.K., J.J.P., S.-H.K., S.-H.Kim, J.-W.S., T.-J.Y., I.-H.C.).

Circulation. Cardiovascular Interventions
|December 7, 2022
PubMed
Summary
This summary is machine-generated.

Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES) showed superior long-term outcomes compared to thick-strut biodegradable polymer biolimus-eluting stents (BP-BES). Patients treated with BP-SES experienced significantly lower rates of target lesion failure at three years.

Keywords:
coronary artery diseasedrug-eluting stentischemiapercutaneous coronary interventionsirolimus

More Related Videos

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

811
Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.8K

Related Experiment Videos

Last Updated: Aug 18, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

811
Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.8K

Area of Science:

  • Cardiovascular Medicine
  • Biomaterials Science
  • Interventional Cardiology

Background:

  • Biodegradable polymer drug-eluting stents (BP-DES) are crucial in coronary artery disease management.
  • Comparative data on BP-DES with varying strut thicknesses are limited.
  • Ultrathin-strut BP-SES have shown promise, necessitating comparison with thicker-strut BP-BES.

Purpose of the Study:

  • To compare the long-term clinical outcomes of ultrathin-strut BP-SES versus thick-strut BP-BES.
  • To evaluate differences in target lesion failure and related adverse events at 3-year follow-up.

Main Methods:

  • The BIODEGRADE trial, a multicenter prospective randomized study, compared ultrathin-strut BP-SES and thick-strut BP-BES.
  • The primary endpoint was target lesion failure at 18 months, with a prespecified analysis of 3-year outcomes.
  • 2341 patients were randomized (1175 to BP-SES, 1166 to BP-BES).

Main Results:

  • At 3 years, target lesion failure occurred in 3.2% of BP-SES patients versus 5.1% of BP-BES patients (P=0.023).
  • Ischemia-driven target lesion revascularization was significantly lower in the BP-SES group (1.5% vs. 2.8%, P=0.035).
  • Landmark analysis confirmed better long-term outcomes for BP-SES, with lower cardiac death and target lesion revascularization rates.

Conclusions:

  • Ultrathin-strut BP-SES demonstrated significantly superior long-term clinical outcomes compared to thick-strut BP-BES at 3 years.
  • The findings suggest a benefit of using ultrathin-strut BP-SES in coronary revascularization.
  • BP-SES may offer improved safety and efficacy in managing coronary artery disease.